PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: Brazil

PE Guidelines
Methodological Guidelines: Economic Evaluation of Health Technologies (2014)
PDF in Portuguese

PE Guidelines Source:
Brazil Ministry of Health
http://www.saude.gov.br

Additional Information:

Last Webpage Update: Monday, January 15, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the documentMethodological Guidelines: Economic Evaluation of Health Technologies (2014)  
Affiliation of authorsUniversities, government. 
Purpose of the documentContribute to the standardization of the local studies in order to improve transparency, review and reproduction of them. 
Standard reporting format includedYes 
DisclosureYes 
Target audience of funding/ author's interestsEither those who conduct HE evaluation or those who evaluate such studies (decision makers) 
PerspectivePreferably the one of the public payer. Societal perspective also possible  
IndicationApproved indications 
Target populationClearly specified 
Subgroup analysisWhen either there is a group of similar alternatives or a variability in clinical practice among a subgroup of patients 
Choice of comparatorMost prevalent treatment in the public system, most used treatment   
Time horizonIt must have as a basis the natural history of the disease in order to capture all relevant costs and consequences 
Assumptions requiredYes 
Preferred analytical techniqueCost-consequence Analysis, CMA, CEA, CUA, CBA   
Costs to be includedIt depends on the perspective of the study: direct costs with/without indirect costs. 
Source of costsGovernment databases and other public databases when necessary   
ModelingYes 
Systematic review of evidencesYes 
Preference for effectiveness over efficacyYes. Efficacy has to be converted into effectiveness by means of appropriate methods. Details must be provided. 
Preferred outcome measureEffectiveness 
Preferred method to derive utilitystandard gamble, time trade-off, personal trade-off or visual analogue scale.  
Equity issues statedYes   
Discounting costsBase case: 5% (0%-10% in S.A.) 
Discounting outcomesBase case: 5% (0%-10% in S.A.) 
Sensitivity analysis-parameters and rangeFor all uncertain parameters, a plausible range must be defined for each parameter. A 2nd order Monte Carlo simulation to be used when applicable. 
Sensitivity analysis-methodsOne-way, multi-way, probabilistic analysis 
Presenting resultsThe report has to be clear, detailed and transparent. A 3-page executive summary must be written in a context accessible to a non-technical reader.   
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Yes 
Portability of results (Generalizability)Yes; details must be provided. 
Financial impact analysisYes 
Mandatory or recommended or voluntaryRecommended 

Acknowledgement: Mario Giorgio Saggia highly contributed to the key features form. Mario Giorgio Saggia, Managing Director, Asigma, São Paulo, Brazil

Country Selection Page | PE Guidelines Index Page